Albireo Pharma (NASDAQ:ALBO) was downgraded by research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued on Tuesday.

ALBO has been the subject of a number of other reports. Wedbush reiterated an “outperform” rating on shares of Albireo Pharma in a research report on Monday, July 16th. Zacks Investment Research upgraded shares of Albireo Pharma from a “hold” rating to a “buy” rating and set a $36.00 price target for the company in a research report on Tuesday, July 24th. Finally, Cowen reiterated a “buy” rating on shares of Albireo Pharma in a research report on Wednesday, August 8th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $59.40.

ALBO stock opened at $32.07 on Tuesday. Albireo Pharma has a 12-month low of $20.25 and a 12-month high of $39.87. The company has a market cap of $397.64 million, a PE ratio of -10.18 and a beta of 1.29.

Albireo Pharma (NASDAQ:ALBO) last posted its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($1.22) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.98) by ($0.24). The firm had revenue of $0.73 million for the quarter, compared to the consensus estimate of $2.00 million. sell-side analysts anticipate that Albireo Pharma will post -3.39 earnings per share for the current year.

In related news, insider Ronald Harold Wilfred Cooper acquired 788 shares of the business’s stock in a transaction that occurred on Tuesday, August 14th. The stock was purchased at an average cost of $31.85 per share, for a total transaction of $25,097.80. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 3.60% of the company’s stock.

Several institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp raised its position in shares of Albireo Pharma by 205.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 32,263 shares of the biopharmaceutical company’s stock worth $1,145,000 after purchasing an additional 21,685 shares during the last quarter. MetLife Investment Advisors LLC acquired a new position in shares of Albireo Pharma during the 2nd quarter worth approximately $167,000. Metropolitan Life Insurance Co. NY acquired a new position in shares of Albireo Pharma during the 2nd quarter worth approximately $118,000. DRW Securities LLC acquired a new position in shares of Albireo Pharma during the 2nd quarter worth approximately $320,000. Finally, Renaissance Technologies LLC raised its position in shares of Albireo Pharma by 16.2% during the 2nd quarter. Renaissance Technologies LLC now owns 107,366 shares of the biopharmaceutical company’s stock worth $3,811,000 after purchasing an additional 14,934 shares during the last quarter. Hedge funds and other institutional investors own 63.38% of the company’s stock.

Albireo Pharma Company Profile

Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.

See Also: Hedge Funds Explained

Analyst Recommendations for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.